Nabriva Therapeutics inks $120 mln Series B

Biotech company Nabriva Therapeutics AG has closed $120 million in Series B funding. Vivo Capital and OrbiMed led the round with participation from EcoR1 Capital, Boxer Capital of Tavistock Life Sciences, HBM, Phase4 Partners, Wellcome Trust, GLSV and Novartis Venture Fund. In addition to the funding, representatives of Vivo Capital and OrbiMed will join Nabriva’s supervisory board.

178 Views

Blueprint Medicines ropes in $50 mln

Blueprint Medicines has raised $50 million in Series C funding. Partner Fund Management led the round with participation from other investors that included Wellington Management Company, RA Capital, Tavistock Life Sciences, Perceptive Advisors, Sabby Capital, Cowen Investments, Redmile Group, Fidelity Biosciences and Third Rock Ventures. Based in Cambridge, Mass., Blueprint Medicines is a developer of kinase inhibitors for genomically defined cancers.

Australian veterinary drug developer Nexvet racks up $31.5 mln

Nexvet Biopharma has closed $31.5 million in Series B financing. Investors included Farallon Capital Management, Adage Capital Partners, Foresite Capital and Tavistock Life Sciences subsidiary fund Boxer Capital. Based in Melbourne, Australia, Nexvet is a veterinary biologic drug developer.

PE HUB Community

Join the 12518 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget